Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
Rhea-AI Summary
Axsome Therapeutics (NASDAQ: AXSM) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026, before U.S. market open. Management will host a conference call at 8:00 a.m. Eastern Time to discuss results and provide a business update.
Live participation: dial (877) 405-1239 (U.S.) or +1 (201) 389-0851 (international). A live webcast will be available on Axsome's Investors > Webcasts & Presentations page at www.axsome.com. A replay will be accessible on the company website for approximately 30 days after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – AXSM
On the day this news was published, AXSM gained 1.90%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AXSM slipped 0.77% while close biotech peers showed mixed moves (e.g., LEGN -0.32%, CYTK +0.45%, ABVX -0.71%, NUVL +0.46%, RYTM +1.18%), and no peers appeared in the momentum scanner, indicating a stock-specific setup rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Phase 3 trial start | Positive | -1.6% | Initiation of FORWARD Phase 3 AXS-14 trial in fibromyalgia patients. |
| Jan 12 | Prelim revenue update | Positive | +4.4% | Preliminary Q4 and 2025 net product revenue with strong year-over-year growth. |
| Dec 31 | Priority Review news | Positive | +22.8% | FDA acceptance and Priority Review of sNDA for AXS-05 in Alzheimer’s agitation. |
| Dec 31 | Pre-NDA meeting | Positive | +22.8% | FDA pre-NDA minutes supporting AXS-12 NDA submission for narcolepsy. |
| Nov 20 | Investor conferences | Neutral | -2.4% | Planned participation in December investor conferences and fireside chats. |
Recent positive clinical and revenue updates often coincided with gains, while one Phase 3 trial initiation and a conferences announcement saw modest declines, indicating mostly aligned reactions with occasional divergences.
Over the past few months, Axsome reported multiple key developments. On Dec 31, 2025, FDA acceptance and Priority Review for AXS-05 and supportive pre-NDA feedback for AXS-12 both saw strong +22.75% reactions. Preliminary Q4 and full-year 2025 revenue on Jan 12, 2026 brought +4.39%. A Phase 3 AXS-14 fibromyalgia trial start on Jan 15, 2026 coincided with a -1.62% move. The current earnings date notice follows this stretch of clinical and commercial catalysts.
Market Pulse Summary
This announcement sets the timetable for Axsome’s Q4 and full-year 2025 report on February 23, 2026, following earlier preliminary revenue disclosures and multiple FDA-related milestones. Shares were trading above the $124.63 200-day moving average and close to the $191.5 52-week high in advance. Investors may focus on how final results compare with the previously reported 2025 net product revenue figures and on any pipeline or regulatory updates discussed during the 8:00 a.m. ET call.
Key Terms
central nervous system (cns) medical
nasdaq financial
AI-generated analysis. Not financial advice.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A replay of the conference call will be available on the Company’s website for approximately 30 days following the live event.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ
When will Axsome Therapeutics (AXSM) report fourth quarter and full year 2025 results?
What time is Axsome's (AXSM) earnings conference call on February 23, 2026?
How can investors join the Axsome (AXSM) live conference call?
Where can I watch the Axsome (AXSM) earnings webcast?
Will there be a replay of Axsome's (AXSM) February 23, 2026 call and for how long?
